Cadila net profit up 53%

CORPORATE SCORECARD

Cadila Healthcare (Zydus Cadila) has posted a consolidated net profit of Rs 234 crore for the year ended March 31, 2007, an increase of 53 per cent over the Rs 152.4 crore net profit for the year ended March 31, 2006.

The total operating income was Rs 1,829 crore, up 23 per cent from Rs 1,485 crore in the corresponding period last year, on a consolidated basis. The company's board of directors recommended a dividend of Rs 4, or 80 per cent per equity share, on the increased capital of 1,25,613,708 equity shares of Rs 5 each for the year ended March 31, 2007.

On a standalone basis, the company has posted a net profit of Rs 37.5 crore for the quarter ended March 31, 2007, as compared with Rs 22.3 crore for the quarter ended March 31, 2006.

The total income (net of excise) increased from Rs 290.3 crore for the quarter ended March 31, 2006 to Rs 354.8 crore for the quarter.

Zydus said the top line growth was driven by the 91 per cent growth in formulation exports, 31 per cent growth in API exports and 54 per cent growth in the consumer business. The growth in exports was buoyed by 186 per cent growth in sales in the US markets, 103 per cent growth in the French market, and 26 per cent growth in exports to other emerging markets. The newly acquired Carnation Nutra Analogue Foods recorded a sales of Rs 43 crore, while the existing consumer business grew by a healthy 23 per cent. Its brand Sugar Free, the leading sweetener in the Indian market, crossed Rs 50 crore in sales in 2006-07.

Zydus said it has filed 26 abbreviated new drug applications (ANDAs) and 11 drug master files (DMFs) during the year, taking the total to 60 ANDA filings and 51 DMFs in the US market.

It has so far received 23 ANDA approvals. The company filed 15 dossiers for new products and 21 site transfer applications for the French market during the year.